“Analytical Method Development and Validation of Simultaneous Estimation of Ambrisentan and Tadalafil in Bulk and Pharmaceutical Dosage Form by HPLC”

International Research Journal of Engineering and Technology (IRJET) e-ISSN: 2395-0056
Volume: 09 Issue: 02 | Feb 2022 www.irjet.net p-ISSN: 2395-0072
© 2022, IRJET | Impact Factor value: 7.529 | ISO 9001:2008 Certified Journal | Page 156
Syed Wajahat Shafaat 1, Aejaz Ahmed 2, Sohail Saleem Khan 1, Momin Affan Abdul Jabbar 1
1Lecturer, Department of Pharmacy, Ismail Mehta College of pharmacy, Ambad 431203 Dist. Jalna Maharashtra,
India.
2Department of Quality Assurances, Ali-Allana College of Pharmacy, Akkalkuwa 425415 Dist. Nandurbar
Maharashtra, India.
------------------------------------------------------------------------***-----------------------------------------------------------------------
Abstract: Aim of this present work is to develop and
validate a simple, efficient and economical method for
simultaneous determination of Ambrisentan and Tadalafil in
bulk and pharmaceuticals dosage form has been developed.
Chromatographic separations of both drugs were achieved
on Inertsil C18 (250×4.6 mm) 5µ using a mobile phase
consisting of buffer (PH 3): methanol (50:50) with flow rate
of 1 ml/min and detection was carried out at 260 nm and 20
µl injection volumes were selected. The linear dynamic
response was found to be in concentration range of 20-60 μg
/ml for Tadalafil and 5-15 μg /ml for Ambrisentan and show
of correlation co-efficient (R2) of 0.999. Accuracy was
determined by recovery studies ranges from 100.898-
99.45145 for Tadalafil and 100.482 – 99.6716 for
Ambrisentan.
Key words: Ambrisentan, Tadalafil, HPLC, Method
Development.
INTRODUCTION
Ambrisentan (AMB) is an anti-hypertensive drug
chemically referred to as (2S)-2-[(4,6-dimethylprimidin-2-
yl) oxy]-3-methoxy-3,3-diphenyl-propanoic acid and its
chemical formula is C22H22N2O4. Ambrisentan (AMB) is an
endothelin receptor antagonist that’s selective to
endothelin type-A (ET-A). AMB belongs to the
antihypertensive class of medicine and use in the
treatment of pulmonary atrial hypertension in patient with
WHO class II or III symptoms. Endothelin is a peptide that
constricts blood vessels and elevates pressure of blood.
AMB decreases blood pressure with in the lungs by
restricts the effects of endothelin-1. The thickening of
blood vessels in the lungs and heart is additionally
inhibited by AMB Fig-1.(1, 2)
Fig-1: Molecular Structure of Ambrisentan
Tadalafil (TADA) chemically known as(6R,12aR)-6-(1,3-
benzodioxol-5-yl)-2-methyl 2,3,6,7,12,12a-
hexahydropyrazino[1',2':1,6] pyrido[3,4-b]indole-1,4-
dione and its empirical formula is C22H19N3O4. TADA is
mainly used to treat erectile dysfunction and pulmonary
arterial hypertensionand it is selective inhibitor of cyclic
guanosine monophosphet (CGMP) and enzyme
phosphodiesterase type 5 (PDE 5) Fig-2(3, 4)
Fig-2: Molecular Structure of Tadalafil
Several HPLC methods have been reported in the literature
for the estimation of Tadalafil available individually and in
combined with other drug. An attempt has been made to
developed simple and reliable HPLC method for the
estimation of Tadalafil and Ambrisentan in bulk and
pharmaceutical formulation. The results of analysis were
validated in accordance with ICH guidelines (5-13)
Material and Methods
Standard of AMB and TADA were obtained from. Tablets
were purchase from the local medical store. Buffer and
“Analytical Method Development and Validation of Simultaneous
Estimation of Ambrisentan and Tadalafil in Bulk and Pharmaceutical
Dosage Form by HPLC”

methanol were obtained from Rankem. All solvent and
reagent were of analytical reagent.
Instrumentation: Gradient system HPLC equipped with
aligned UV detector was used throughout the analysis. The
analysis column inertsil C18 250mm x 4.6mm, 5µ thermo
scientific was used as a stationary phase. The instrumental
settings were a flow of 1.0 ml/min and injection volume
20µL column oven temperature was ambient.
Buffer preparation: 6.8 gm Potassium dihydrogen
phosphate buffer was transferred to 1000ml beaker and
800 ml water was added shacked to dissolve and volume
was made up with water, pH 3.0 was adjusted with diluted
o-Phosphoric acid.
AMB Standard stock solution (100 µg/ml): Accurately
weighed 10mg of AMBRS and Transferred to 100ml
volumetric flask and volume was made up with the
Diluent.
TAD Standard stock solution (400 µg/ml): Accurately
weighed 40mg of TAD RS and Transferred to 100ml
volumetric flask and volume was made up with the
Diluent.
Standard Working solution (AMB 100µg/ml, TAD
40µg/ml): 1ml of standard stock solution was transferred
to 10ml volumetric flask and volume was made up with
the Diluent.
Optimization Chromatographic Conditions: various
combination of mobile phase was screened with relevancy
to resolution, theoretical plate, capacity factor and other
system suitability parameters. Finally the separation was
performed with freshly prepared mobile phase comprises
of Buffer (pH 3): Methanol (50:50) at rate of flow of
1.0ml/min. 260nm wavelength, injection volume of 20 μL
temperature was maintained during the whole process to
get symmetric peak of AMB and TADA.
Method validation (14, 15)
The developed HPLC method was validated by
determining the following parameter.
System suitability: system suitability test are a
fundamental part of liquid chromatography it ensure that
system is working correctly. Standard solution of AMB and
TADA was injected into the chromatographic system and
recorded the chromatograms. System suitability
parameter such as number of theoretical plate, retention
time, and telling factor were evaluated.
Linearity: The linearity of method was performed by
analyzing a standard solution of AMB and TADA to get a
solution in a concentration range is 20-60 µg/ml 05-15
µg/ml for TADA and AMB respectively. The area at which
level was calculated and the therefore the graph of area
versus concentration was plotted. The correlation
coefficient was calculated in linearity plot.
Limit of detection (LOD) and limit of quantitation (LOQ):
LOD and LOQ of AMB and TADA were determined by
calibration curve used to determine method linearity.it
may be calculated as
LOD = 3.3 × (SD/slop)
LOQ =10 × (SD/slop)
Where
SD= the standard deviation of response (peak area)
SLOP= mean slop of the calibration curve
Precision: precision of the proposed method was
determined by injection six replicates of unknown
concentration of AMB and TADA are analyzed by injecting
them into a HPLC column on the identical day. The
intermediate precision was estimated by injecting sample
prepared at the identical concentration on three different
days. The %RSD for the AMB and TADA WAS calculated.
Accuracy: the accuracy of this method was performed at
three different levels (80%, 100% and 120%) by the
adding of unknown amount of standard to the sample at
each level. Each sample was injected thrice.
Robustness: robustness is that the measure of optimized
method capacity to stay unaffected by small but deliberate
variation in method parameters like mobile phase flow
rate. (±0.2 ml/min), P.H (±0.2) and PH ±2S.
Results
Optimization of chromatographic conditions:
Optimized chromatographic condition for estimation of
AMB and TAD are finalized shown in below. A
representative chromatogram is shown in Fig-3.
 Column: Inertsil C18 (250x4.6 mm)
 Mobile Phase: Buffer (pH 3.0): Methanol (50:50)
 Flow Rate: 1.0 ml/min
 Detection Wavelength: 260 nm
 Runtime: 6 min
 Injection volume: 20.0μl

Fig-3: Chromatogram of Standard AMB and TADA
System suitability
The system suitability was performed by injecting mix
standard solution containing 400μg /ml Tadalafil and
100μg /ml Ambrisentan in six replicates. For two of them
the peak asymmetric were< 1.5 and the theoretical plate
number is > 2000and % RSD of Ambrisentan and Tadalafil
was less than 2. The result indicates that the system
suitability parameter is within the acceptable limit. The
results are shows in Table 1.
Table 1: Results for System Suitability Test
Parameters AMB TADA
Theoretical plates per
column
9600 4516
Symmetry
factor/tailing factor
1.341 1.467
Retention time (min) 7.077 3.807
Resolution - -
Linearity
The linearity of the method was established by
determining the constructing calibration graph between
tested calibration level and corresponding peak area for
AMB and TADA in triplicate. Over a range of 5 – 15μg / ml
and 20 – 60μg /ml respectively. The correlation coefficient
was > 0.999 for all two drugs. The results are given in
Table-2 and Fig-6 (a and b).
Table 2: Linearity Data for AMB and TADA
Sr.
No
Tadalafil Ambrisentan
Conc.
(Mcg/Ml)
Area
Conc.
(Mcg/
Ml)
Area
1 20 704.631 5 738.555
2 30 1024.673 7.5 1075.825
3 40 1372.279 10 1438.651
4 50 1731.691 12.5 1822.059
5 60 2052.149 15 2139.902
Co-Efficient
Regression
0.99979642
6
0.99962375
8
Limit of detection (LOD) and limit of quantitation
(LOQ)
The LOD and LOQ were found to be 0.117 and 0.357μg /ml
for TADA and 0.0096 and 0.00088μg /ml for AMB. THE
results are given in Table 3.
Table-3: LOD and LOQ
Drug LOD LOQ
Tadalafil 0.117 0.357
Ambrisentan 0.0096 0.00088
Precision
Method precision / repeatability
The % RSD value for six replicate injection of a
unknown concentration of ambrisentan 100μg /ml and
tadalafil 400μg /ml. carried out on the same day was found
to be < 2 % which indicate that the method repeatable. The
results for method precision are given in Table-4.

Table 4: Intraday Precision Data for Estimation of AMB
and TADA
AMBRISENTAN
Sr
n
o
Conc.ug
/ml Area SD* %RSD**
1
50%
731.064
3.0708 0.4192
730.327
735.976
2 100%
1430.07
8.8767 0.6238
1412.99
1425.73
3 150%
2174.31
15.0594 0.69511
2149.1
2175.97
*standard deviation ** % relative standard deviation
System precision / intermediate precision
Intermediate precision was determined by measuring the
peak area of six replicate was inject into HPLC system and
was analyzed and the were found within the acceptable
limit (%RSD) intermediate precision given in Table-5.
Table 5: Interday Precision Data for Estimation of AMB
and TADA
TADALAFIL
Sr.no
Conc.
μg/ml
Area SD* %RSD**
1 50% 731.064 3.0708 0.4192
730.327
735.976
2 100% 1430.07 8.8767 0.6238
1412.99
1425.73
3 150% 2174.31 15.0594 0.69511
2149.1
2175.97
Accuracy
The percentage recovery was calculated by preparing
standard concentration of AMB and TADA with
concentration level of 80%, 100% and 120%. The
percentage recovery obtained was found to be in the range
of 100.89, 100.71, 99.451% for TADA and100.482, 99.814,
and 99.671% for AMB. The acceptable limits of mean
recovery are 100% - 102%. Good recovery of the spiked
drugs was obtained at each added concentration.
Robustness
The method was found to be robust when minor
changes were made in optimized chromatographic
condition such as mobile phase flow rate (+ 0.2 ml/ min),
M.P (+ 0.2), and pH (+ 0.2).it was observed that there was
no marketing change in the analytical data of the drug
which indicate good reliability during normal usage. The
results are given in Table-6 and 7.
AMRISENTAN
Sr No
Conc.
μg/ml
Area SD* %RSD**
1
50%
731.064
3.0708 0.4192
730.327
735.976
2 100%
1430.07
8.8767 0.6238
1412.99
1425.73
3 150%
2174.31
15.0594 0.69511
2149.1
2175.97

Table-6: Robustness Data for TADA
Sr.
No.
Flow
rate
+2
Flow
rate -
2
M.P.
+2
M.P. -
2
pH +2 pH -2
1 1178.
407
1545.
962
1230.
075
1517.
092
1452.
527
1270.
067
2 1179.
558
1535.
143
1230.
415
1509.
492
1445.
259
1241.
154
3 1173.
621
1532.
095
1247.
379
1518.
645
1425.
965
1253.
56
avg.
are
a
1177.
195
1537.
733
1235.
956
1515.
076
1441.
25
1254.
927
SD
3.148
507
7.287
372
9.893
78
4.898
116
13.72
724
14.50
489
%R
SD
0.267
458
0.473
904
0.800
496
0.323
292
0.952
453
1.155
836
*MP = mobile phase
Table-7: Robustness Data for AMB
Sr.
no.
Flow
rate
+2
Flow
rate -
2
MP*.
+2
MP. -
2
pH +2 pH -2
1 1234.
479
1620.
637
1288.
591
1590.
368
1522.
679
1309.
338
2 1235.
705
1609.
288
1295.
027
1582.
383
1515.
034
1300.
182
3 1223.
479
1606.
067
1285.
961
1598.
218
1504.
417
1313.
194
avg.
are
a
1231.
221
1611.
997
1289.
86
1590.
323
1514.
043
1307.
571
SD
6.732
733
7.653
534
4.664
25
7.917
596
9.171
217
6.683
477
%R
SD
0.546
834
0.474
786
0.361
609
0.497
861
0.605
743
0.511
137
Conclusion: The proposed method was found to be
simple, accurate, precise and rapid HPLC method suitable
for the estimation of Ambrisentan and Tadalafil in bulk
and tablet dosage form. All the parameters meet the
standard of ICH guidelines for method validation and
found to be simple, sensitive, accurate and precise. It can
be concluded that the reported method is more economical
and can find practical application & may be recommended
for routine and QC analysis of the investigated drugs to
provide simple, accurate and reproducible quantitative
analysis for the determination of Ambrisentan and
Tadalafil in bulk and tablet dosage form.
Acknowledgment: The authors are thankful to presser
JUII’S G.M. Vastanvi, principal and guide for their
encouragement and support we also wish to thanks to Mr.
Ketan Patel molecule laboratory.
References
1. Drug Profile of Ambrisentan Available
https://pubchem.ncbi.nlm.nih.gov/compound/A
mbrisentan[Last Access In 12/ 3/ 19]
2. Drug Profile of Ambrisentan Available in
https://www.drugs.com/mtm/ambrisentan.html
[last access in 12/3/ 19]
3. Drug Profile of Tadalafil Available in
https://www.drugs.com/tadalafil.htm [last access
in 12/3/ 19].
4. Drug Profile of Tadalafil Available in
https://pubchem.ncbi.nlm.nih.gov/compound/Ta
dalafil [last access in 12/3/ 19]
5. A. Kumar, Dr. V. Kumar, Dr. R. M. Singh, J.
Chaudhari, and P. Kori, “Reverse Phase – High
Performance Liquid Chromatographic Method for
Simultaneous Estimation of Sildenafil Citrate and
Tadalafil In Tablets Dosage Form” International
Journals of Advance Research and Development.,
vol. 3, no. 4, (2018), pp. 326-330.
6. A.K. Kumar, M.Balakrishnan, and
K.B.Chandrasekhar, “A New Validated
Simultaneous Method Development by RP-UPLC
for the Estimation of Tadalafil and Dapoxetine In
Bulk and Pharmaceutical Dosages” International
Journal of Pharmacy and Biological Sciences. Vol.
8, no. 2, (2018), pp. 65-73.
7. H. Mohammed, A. S. Ahmed, W. A. Dayyih, E.
Mallah, and T. Arafat “Simultaneous Estimation of
Esomeprazole and Tadalafil In Pharmaceutical
Formulations Using High Performance Liquid
Chromatography” Journal of Applied
Pharmaceutical Science., vol. 6, no. 04, (2016), pp.
052-059.
8. R. Karthikeyan, O. S. Koushik, and P. S. Babu
“Simple Validated Rp-Hplc Method for Estimation
of Ambrisentan in Pharmaceutical Dosage Forms”
International Bulletin of Drug Research., vol. 5, no.
9, (2015), pp. 1-18.
9. Mohammed Nazeerunnisa, Lakshmi Garikapati,
and Syama Sundar Bethanabhatla: Development

and Validation of A Stability-Indicating Rp-Hplc
Method For Determination of Ambrisentan In Bulk
Drugs. Malaysian Journal of Analytical Sciences
2015; 19(3): 595 – 602.
10. Aziz Unnisa, Yogesh Babu, Santosh kumar suggu,
and Siva Chaitanya. RP-HPLC-PDA method
development and validation for the analysis of
Tadalafil in bulk, pharmaceutical dosage forms
and in-vitro dissolution samples. Journal of
Applied Pharmaceutical Science 2014; 4 (12):
072-076.
11. Burla Sunitha Venkata Seshamamba,Peruri Veera
Venkata Satyanarayana, and Chandra Bala
Sekaran: Validated Stability Indicating High
Performance Liquid Chromatographic Method for
the Determination of Ambrisentan in
Pharmaceutical Dosage Form. Pharmaceutical
sciences 2014; 19(4): 109-115.
12. Jayvadan K. Patel, Nilam K. Patel: Stability-
Indicating RP-HPLC Method for the Determination
of Ambrisentan and Tadalafil in Pharmaceutical
Dosage Form. Scientia Pharmaceutica 2014; 8(2):
749–763.
13. M. Rajeshwari, A. Chenthilnathan and K. Rama:
Validated Rp-Hplc Method For Simultaneous
Estimation of Tadalafil and Dapoxetine
Hydrochloride In Combined Pharmaceutical
Dosage Forms. Research Article Pharmaceutical
Sciences 2014; 4(2): 72-82.
14. ICH. International Conference on Harmonization
of Technical Requirements for Registration of
Pharmaceuticals for Human Use, Validation of
analytical procedure: Text and Methodology Q2
(R1); 2005.

“Analytical Method Development and Validation of Simultaneous Estimation of Ambrisentan and Tadalafil in Bulk and Pharmaceutical Dosage Form by HPLC”

More Related Content

Similar to “Analytical Method Development and Validation of Simultaneous Estimation of Ambrisentan and Tadalafil in Bulk and Pharmaceutical Dosage Form by HPLC” (20)

More from IRJET Journal (20)

Recently uploaded (20)

“Analytical Method Development and Validation of Simultaneous Estimation of Ambrisentan and Tadalafil in Bulk and Pharmaceutical Dosage Form by HPLC”